Clinical Trials
25 trialsGemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
A Study of ERAS-601 in People With Chordoma
Memorial Sloan Kettering Cancer Center
SC9/ABX
Northwestern University
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Massachusetts General Hospital
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
STARTRK-NG
Hoffmann-La Roche
Regbone
Institute of Mother and Child, Warsaw, Poland
AMPHISARC
Centre Leon Berard
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
LIBRETTO-121
Eli Lilly and Company
DUET-1
Sotio Biotech Inc.
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
PRESERVE-001
OncoC4, Inc.
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
Bambino Gesù Hospital and Research Institute
INJECTABL-1
Immunophotonics, Inc.
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center